These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15658422)

  • 41. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
    Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Activated protein C resistance: role in venous and arterial thrombosis].
    Emmerich J; Alhenc-Gelas M; Aiach M; Fiessinger JN
    Arch Mal Coeur Vaiss; 1996 Jun; 89(6):741-5. PubMed ID: 8760661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resistance to activated protein C in an unselected population of patients with pulmonary embolism.
    Desmarais S; de Moerloose P; Reber G; Minazio P; Perrier A; Bounameaux H
    Lancet; 1996 May; 347(9012):1374-5. PubMed ID: 8637344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of Hereditary Thrombophilia: Performance of Protein C (PC) Testing.
    Marlar RA; Gausman JN
    Methods Mol Biol; 2017; 1646():145-151. PubMed ID: 28804825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance.
    Jennings I; Kitchen S; Woods TA; Preston FE
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):451-3. PubMed ID: 10695775
    [No Abstract]   [Full Text] [Related]  

  • 47. [Prevalence, diagnosis and clinical significance of thrombophilia caused by Va factor resistance to activated C protein].
    Barkagan ZS; Tsyvkina LP; Mamaev AN; Tseĭmakh IIa
    Vestn Ross Akad Med Nauk; 1997; (2):39-41. PubMed ID: 9376729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inherited and secondary thrombophilia.
    Cohoon KP; Heit JA
    Circulation; 2014 Jan; 129(2):254-7. PubMed ID: 24421360
    [No Abstract]   [Full Text] [Related]  

  • 49. Activated protein C resistance and inherited thrombosis.
    Rodgers GM
    Am J Clin Pathol; 1995 Mar; 103(3):261-2. PubMed ID: 7872247
    [No Abstract]   [Full Text] [Related]  

  • 50. Pros and cons of thrombophilia testing: pros.
    Martinelli I
    J Thromb Haemost; 2003 Mar; 1(3):410-1. PubMed ID: 12871438
    [No Abstract]   [Full Text] [Related]  

  • 51. Modified test for activated protein C resistance.
    Jorquera JI; Montoro JM; Fernández MA; Aznar JA; Aznar J
    Lancet; 1994 Oct; 344(8930):1162-3. PubMed ID: 7864945
    [No Abstract]   [Full Text] [Related]  

  • 52. Thrombophilia: the new factor is old factor V.
    Tuddenham EG
    Lancet; 1994 Jun; 343(8912):1515-6. PubMed ID: 7911865
    [No Abstract]   [Full Text] [Related]  

  • 53. [Activated protein C resistance in the Japanese].
    Ozawa T
    Rinsho Ketsueki; 1996 Sep; 37(9):790-3. PubMed ID: 8914464
    [No Abstract]   [Full Text] [Related]  

  • 54. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S.
    Denson KW; Haddon ME; Reed SV; Davidson S; Littlewood TJ
    Thromb Res; 1996 Jan; 81(1):151-6. PubMed ID: 8747530
    [No Abstract]   [Full Text] [Related]  

  • 55. The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
    Kambayashi J; Fujimura H; Kawasaki T; Sakon M; Monden M; Suehisa E; Amino N
    Thromb Res; 1995 Jul; 79(2):227-9. PubMed ID: 7676410
    [No Abstract]   [Full Text] [Related]  

  • 56. [Activated protein C resistance (APC resistance)].
    Gohchi K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():678-80. PubMed ID: 15658422
    [No Abstract]   [Full Text] [Related]  

  • 57. Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.
    Dahlbäck B
    Rev Invest Clin; 1997 May; 49 Suppl 1():3-5. PubMed ID: 9291738
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Molecular marker for anticoagulant protein C pathway (APC-PCI complex)].
    Hamada T; Kamada H; Suzuki K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():674-7. PubMed ID: 15658421
    [No Abstract]   [Full Text] [Related]  

  • 60. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.